How to appeal a UnitedHealthcare pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology

Cited policy: UHC Commercial: Adalimumab (Humira) for Juvenile Idiopathic Arthritis + similar TNF inhibitor / IL-6 / abatacept policies (mirrors ACR 2019 Treatment Recommendation)

ACR 2019 JIA Treatment Recommendation: TNF inhibitor / IL-6 / abatacept after MTX 3-6 months inadequate response on JADAS-10 OR aggressive disease features at presentation; FDA on-label peds age (Humira >=2 yr); peds rheum prescribing.

How UnitedHealthcare denies pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology — and how to counter it

Where UnitedHealthcare pushes back: 1) MTX trial 'too short'; 2) JADAS not documented; 3) Step therapy through additional NSAIDs / IA steroid not exhausted; 4) 'General pediatrician can manage'.

Counter-arguments that hold up: Cite ACR 2019 JIA Treatment Recommendation (Ringold) — TNF inhibitor when MTX inadequate at 3-6 months. Submit JADAS-10 trajectory + objective active joint count + slit-lamp documentation (uveitis screening). Lovell NEJM 2008 RCT of adalimumab JIA. FDA approval Humira JIA age >=2 (2008). Document peds rheum credentials + slit-lamp + multidisciplinary care (PT/OT, ophtho).

What UnitedHealthcare typically denies for pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Peds congenital heart surgery
• Kawasaki workup + IVIG
• Pediatric ECMO
• Peds EoE workup + therapy
• Peds IBD biologic
• Peds asthma biologic / admission

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.